Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 50 g/l; potassium chloride, quantity: 2.24 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - the potassium chloride in glucose (5%) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of potassium and chloride ion concentrations. this is also an alternative route of administration for the patients who are unable to take potassium orally or if hypokalaemia is severe. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 50 g/l; potassium chloride, quantity: 1.5 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - the potassium chloride in glucose (5%) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of potassium and chloride ion concentrations. this is also an alternative route of administration for the patients who are unable to take potassium orally or if hypokalaemia is severe. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - furosemide 10mg - solution for injection - 10 mg/ml - active: furosemide 10mg excipient: hydrochloric acid sodium hydroxide ph adjustment sodium chloride sodium hydroxide water for injection - furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. furosemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium nitroprusside, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections - sodium nitroprusside baxter concentrated injection is indicated for:,1. immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside.,2. producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate.,3. short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 6.43 g/l; potassium chloride, quantity: 1.19 g/l; magnesium chloride hexahydrate, quantity: 3.25 g/l; calcium chloride dihydrate, quantity: 0.176 g/l - solution - excipient ingredients: water for injections; hydrochloric acid - other conditions: the ph of the solution must be adjusted to 7.4 to 7. 8 with 10ml of sodium bicarbonate 8.4% w/v injection bp (not supplied) before use. indications: following ph adjustment with 10ml of sodium bicarbonate 8.4% w/v injection bp, cardioplegia "a" solution is used in combination with ischaemia and hypothermia to induce cardiac arrest during open heart surgery and to preserve the myocardium during asystole.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 50 g/l; sodium chloride, quantity: 4.5 g/l - injection - excipient ingredients: water for injections; hydrochloric acid - sodium chloride and glucose intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium and chloride ion concentrations. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 250 g/l - injection, solution - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: hydrochloric acid; water for injections - indications as at 9 october 2002: sodium chloride (0.9%) intravenous infusion is indicated for extracellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 100 g/l - injection, intravenous infusion - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 500 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)